Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast

The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co), which gained label expansion in January 2023 in the adjuvant setting, have broad applicability in many stages and settings of NSCLC and dominate the market, while biomarker-targeted therapeutics increasingly drive segmentation of the space. The range of drug-addressable disease drivers continues to expand, with the entry of KRAS inhibitors and the 2022 approval of Enhertu, the first targeted therapy for previously treated metastatic HER2-mutant NSCLC. Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus further new market entrants, will further drive competition in this commercially lucrative market.

Questions answered

  • How will the recent and expected new market entrants shape the treatment landscapes across the various settings and stages (I-IV) of NSCLC?
  • Which therapy options will dominate the commercially lucrative first-line metastatic NSCLC setting?
  • What are the most promising pipeline products, and what is their forecast uptake and patient share in NSCLC?
  • What are NSCLC’s key market drivers and constraints, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports